Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from AlloVir ( (ALVR) ).
AlloVir, Inc. has announced a merger with Kalaris Therapeutics to form a company focused on retinal diseases, leveraging Kalaris’ TH103 therapy, a novel anti-VEGF treatment. The merger will see Kalaris stockholders own a majority stake, with the combined entity expected to have $100 million in cash, potentially supporting operations into late 2026. The move is set to accelerate the clinical development of TH103, which is currently in Phase 1 trials for neovascular age-related macular degeneration, with results anticipated by Q3 2025.
See more data about ALVR stock on TipRanks’ Stock Analysis page.
